Up a level |
Pratt, Guy, Yap, Christina, Oldreive, Ceri, Slade, Daniel, Bishop, Rebecca, Griffiths, Mike, Dyer, Martin JS, Fegan, Chris, Oscier, David, Pettitt, Andrew et al (show 9 more authors)
(2018)
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY, 182 (3).
pp. 429-433.
Eyre, Toby A, Hildyard, Catherine, Hamblin, Angela, Ali, Ayesha S, Houlton, Aimee, Hopkins, Louise, Royston, Daniel, Linton, Kim M, Pettitt, Andrew, Rule, Simon et al (show 11 more authors)
(2019)
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
HEMATOLOGICAL ONCOLOGY, 37 (4).
pp. 352-359.